Fortress Biotech repaid USD 15.00 million debt. Fortress Biotech stock is valued at USD 64.7 million

Published on 10/21/2026 at 02:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fortress Biotech repaid USD 15.00 million under Oaktree on September 30, 2026. Fortress Biotech stock was last at USD 1.94 on October 20, 2026.

Debt repayment strengthens balance sheet

Fortress Biotech repaid USD 15.00 million under its Oaktree facility on September 30, 2026.
The credit agreement began at USD 50.00 million and was amended on December 12, 2025.
Fortress Biotech stock was last at USD 1.94 at 4:00 p.m. ET on October 20, 2026.
The company had a USD 64.7 million market capitalization as of October 20, 2026.

FBIO, US34960Q3074, Illustration mit AI erstellt.

Fortress Biotech (US34960Q3074) repaid USD 15.00 million of debt on September 30, 2026, ending the remaining principal under its Oaktree credit facility. The company had also paid accrued interest, a prepayment fee and closing costs, according to the SEC.

The repayment was the latest balance-sheet step in a facility that originally totaled USD 50.00 million. For investors, the key change is the comparison between the USD 15.00 million principal repaid and the larger credit agreement that had supported the company since July 2024.

What changed after the repayment?

The SEC filing shows that the Oaktree agreement was amended on December 12, 2025, and February 22, 2026. Each amendment related to the USD 50.00 million senior secured facility. The September 30 repayment satisfied the remaining principal and released the liens securing the agreement.

Three balance-sheet milestones

On December 12, 2025, Fortress Biotech amended its USD 50.00 million Oaktree facility. On February 22, 2026, the company amended the same USD 50.00 million agreement again. On September 30, 2026, it repaid the remaining USD 15.00 million and terminated the facility, as detailed by Fortress Biotech.

What dates frame the story?

The filing date was October 1, 2026, while the debt repayment itself occurred on September 30, 2026. The latest reported quarterly period ended June 30, 2026, according to the company investor-relations page.

Stock value remains modest

Fortress Biotech stock was last at USD 1.94 on the Nasdaq Capital Market on October 20, 2026 at 4:00 p.m. ET. Its market capitalization was USD 64.7 million at the same market-data timestamp, placing the repaid principal at a substantial proportion of the company value.

The last available quote was USD 1.94 in the United States on October 20, 2026 at 4:00 p.m. ET.